Know Cancer

forgot password

Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes

Open (Enrolling)
Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis

Thank you

Trial Information

Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes

Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF), also
known as the Philadelphia Chromosome negative myeloproliferative disorders (MPDs), are not
congenital, but acquired. The purpose of this project is to find genes whose mutations cause
these disorders, as well as improve diagnostic measures for these diseases. When this is
accomplished new therapies to control and eventually cure the disease can be designed.

All subjects will be asked to donate 4-6 teaspoons of blood. On occasion, if the blood
cells from a particular sample do not grow well and the DNA from that sample is used up or
other tests are needed, we may ask to collect additional samples. In patients who have
undergone a bone marrow biopsy as part of their clinical evaluation, we will test the
reproducibility between pathologists for the revised 2008 WHO diagnostic criteria to
diagnose myeloproliferative disorders (MPD).

Inclusion Criteria:

1. Patients with an elevated hemoglobin concentration (>18 in males and >16 in females)
and who are suspected to have congenital or acquired primary polycythemia

2. Patients with a persistent thrombocytosis (>400,000) that does not have an obvious
secondary cause

3. Patients with a bone marrow biopsy that shows increased cellularity and fibrosis

4. Patients where there is clinical concern for primary myelofibrosis, such as anemia in
combination with leukocytosis, thrombocytosis, splenomegaly and/or a
leukoerythroblastic blood smear

5. Patients with thrombosis at unusual sites, such as Budd-Chiari syndrome, can have
early PV before hemoglobin is elevated, these patients will also be included.

Exclusion Criteria:

1. Subjects who have a known acquired cause of polycythemia (increased
hemoglobin/hematocrit) such as people living in high altitudes (in excess of 14,000
feet), subjects with heart disease, left to right heart shunt, severe hypoxia or
severe pulmonary disease will be excluded from this study.

2. Subjects with a known acquired cause of thrombocytosis.

3. Subjects will be excluded if they cannot demonstrate decision making capacity
sufficient to agree or decline the blood drawing or use of their blood for the study.

Type of Study:


Study Design:

Observational Model: Case Control, Time Perspective: Prospective

Outcome Measure:

Identify genes whose mutations cause Polycythemia Vera, Essential Thrombocythemia and Primary Myelofibrosis.

Outcome Time Frame:


Safety Issue:


Principal Investigator

Josef T Prchal, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Utah


United States: Institutional Review Board

Study ID:




Start Date:

July 2006

Completion Date:

March 2015

Related Keywords:

  • Polycythemia Vera
  • Essential Thrombocythemia
  • Myelofibrosis
  • Myeloproliferative Disorders
  • Hematological Malignancies
  • Polycythemia Vera
  • Essential Thrombocythemia
  • Myelofibrosis
  • Genetics
  • Chronic Leukemia
  • Primary Myelofibrosis
  • Polycythemia
  • Polycythemia Vera
  • Thrombocythemia, Essential
  • Thrombocytosis



University of Utah Salt Lake City, Utah